marginal ulcer

(redirected from Recurrent ulcer)
Also found in: Medical.

marginal ulcer

[′mär·jən·əl ′əl·sər]
(medicine)
A peptic ulcer of the jejunum on the efferent margin of a gastrojejunostomy.
References in periodicals archive ?
The primary endpoint was a composite of upper gastrointestinal bleed or recurrent ulcer.
In a randomized trial of patients who had had previous NSAID-induced ulcer bleeding, the COX 2 inhibitor celecoxib was shown to be as effective as a combination of the NSAID diclofenac and the PPI omeprazole for prevention of recurrent ulcer bleeding.
These results "confirm our hypothesis that esomeprazole can effectively prevent recurrent ulcer in clopidogrel users who have a peptic ulcer history," the investigators said.
A double-blind randomised controlled trial (5) which enrolled patients at high risk for recurrent ulcer bleeding showed that a combination of a high-dose PPI (esomeprazole 20 mg twice daily) and celecoxib (200 mg twice daily) was significantly better than celecoxib alone in preventing GI complications.
The study found that the number of foot ulcers, recurrent ulcers, duration of first ulcer, duration of recurrent ulcer, total amputations, and mean cost per person increased with a VDT greater than or equal to 25V as compared to a VDT less than 25V.
Clopidogrel should not be substituted for aspirin in patients who have previous ulcer bleeding in an effort to reduce the risk of recurrent ulcer bleeding.
1,2) This opinion was validated by the results of a recent RCT that found that treatment with esomeprazole plus celecoxib was significantly superior to celecoxib alone for the prevention of recurrent ulcer bleeding (FIGURE 1).
Clopidogrel should not be substituted for aspirin as a strategy to reduce recurrent ulcer bleeding in high-risk patients, because it is inferior to the combination of aspirin plus PPIs.
Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.
pylori infection require treatment with anti-infective agents to address the third goal, whether on first presentation or with recurrent ulcer disease.
The 13-month cumulative incidence of recurrent ulcer bleeding in this trial was 0% in subjects randomized to the combination therapy, compared with 8.
Full browser ?